Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | ATR-101 |
Synonyms | |
Therapy Description |
Nevanimibe (ATR-101) is a selective inhibitor of Acyl-CoA Acyltransferase 1 (SOAT1) that leads to apoptosis in adrenal and adrenal cancer cells (PMID: 26986192, PMID: 31984451). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
ATR-101 | Nevanimibe|PD-132301 | Nevanimibe (ATR-101) is a selective inhibitor of Acyl-CoA Acyltransferase 1 (SOAT1) that leads to apoptosis in adrenal and adrenal cancer cells (PMID: 26986192, PMID: 31984451). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT01898715 | Phase I | ATR-101 | Phase 1 Study of ATR-101 in Subjects With Advanced Adrenocortical Carcinoma | Completed | USA | DEU | 0 |